SHANGHAI, Dec. 30, 2025 /PRNewswire/ — Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of its self-developed innovative anti-IL-11 monoclonal antibody (R&D code: 9MW3811) for pathological scarring recently completed the first patient dosing in China, becoming the world’s first IL-11 targeting drug candidate to […]